InflaRx N.V. (NASDAQ:IFRX) is one of the
10 Most Volatile Penny Stocks to Buy Now.
On May 13, 2026, Raymond James upgraded InflaRx N.V. (NASDAQ:IFRX) to Strong Buy from Outperform with a price target of $9, up from $7. Raymond James said sentiment is increasingly supported by a constructive view of InflaRx’s izicopan program in AAV, backed by a recent $150M financing that extends runway into proof-of-concept development. The firm also cited preclinical and early clinical signals suggesting potentially improved potency, reduced hepatotoxicity risk, and simpler dosing versus avacopan.
On May 11, 2026, H.C. Wainwright analyst Matthew Keller raised the firm’s price target on InflaRx N.V. (NASDAQ:IFRX) to $8 from $6 and maintained a Buy rating on the shares. Keller cited the company’s adjusted clinical focus on ANCA-associated vasculitis, inflammatory renal diseases, and potential partnering of the hidradenitis suppurativa program following the recent corporate update.
On May 6, 2026, InflaRx N.V. (NASDAQ:IFRX) announced plans to develop izicopan, an oral C5a receptor inhibitor, in AAV, a life-threatening kidney disorder. The company is conducting Phase 2 planning for izicopan in AAV and evaluating multiple development approaches, including a potential expedited path to the commercial market. InflaRx also aims to establish rapid proof of concept for izicopan across a broader range of complement-mediated life-threatening kidney diseases through open-label studies expected to begin generating clinical data next year in certain indications.
InflaRx N.V. (NASDAQ:IFRX) discovers and develops inhibitors using C5a technology in Germany and the United States.
While we acknowledge the potential of IFRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.